Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





DECABORANE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 17702-41-9; **Chemical Formula:** B10H14
OSHA’s former limit for decaborane was 0.05 ppm TWA, with a skin notation. The ACGIH has a TLV-TWA of 0.05 ppm and a TLV-STEL of 0.15 ppm, also with a skin notation. The proposal retained the 8-hour TWA of 0.05 ppm and added a 0.15-ppm STEL, with a skin notation, and the final rule establishes these limits. NIOSH (Ex. 8-47, Table N1) concurs that these limits are appropriate. Decaborane forms colorless crystals that are stable at ordinary temperatures and have a pungent odor.
The acute toxicity of decaborane is extremely high for small laboratory animals. The 40-hour LC(50)s for rats and mice are 46 and 12 ppm, respectively (Schechter 1958/ Ex. 1-363). Dermal LD(50)s for rabbits and rats are 71 and 740 mg/kg, respectively (Svirbely 1954a/Ex. 1-385). Acute exposures to decaborane cause loss of coordination, convulsions, weakness, tremors, and hyperexcitability. Decaborane’s primary effects are on the kidneys and liver. Studies of repeated exposures to this substance suggest that the toxicity of decaborane is intermediate between that of pentaborane and diborane. The ability of decaborane to penetrate the skin is particularly notable, as is its toxicity to the central nervous system in some species, e.g., rats and rabbits (Svirbely 1954a/Ex. 1-385, 1954b/Ex. 1-530, and 1955/Ex. 1-386). Monkeys showed decreased ability for certain operant behaviors when injected with doses of 3 to 6 mg/kg decaborane (Reynolds et al. 1964, as cited in ACGIH 1986/Ex. 1-3, p. 169). Central nervous system toxicity has been observed in humans exposed occupationally (Krackow 1953/Ex. 1-344). No comments other than NIOSH’s were received on the health effects of decaborane.
OSHA is retaining its 8-hour TWA PEL of 0.05 ppm TWA and skin notation, and adding a 15-minute STEL of 0.15 ppm for decaborane. The Agency concludes that these limits will provide protection against the significant risks of material health impairment in the form of neuropathy and kidney and liver damage possible in the absence of a short-term limit for decaborane.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue